Dexcom: New Addressed Customer Segments, Margin Increase, and $1 Billion Share Buyback Shape Q3!
Reading Time: 3 minutes
Sales in Q3 2026 increase by 11% year-on-year to $1.34 billion. The gross margin reaches 65.1%, a level last recorded in late 2022. A new share buyback program of $1.0 billion underscores the capital allocation strategy. Focus on Continuous Glucose Monitoring The business model of Dexcom (DXCM) is based on the development and distribution of continuous glucose monitoring (CGM) systems. This technology enables seamless monitoring of blood sugar levels without traditional finger pricks. Relevant growth trends include market penetration...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
